AgeTech Platform Focuses on Human-Centered Care for the Aging Population with Chase Idleman Arlow

Chase Idleman, Chief Executive Officer of Arlow, is leveraging emerging AgeTech and the longevity economy to develop solutions for an aging population, their families, and caregivers. With a human-centered approach to the entire aging process, Arlow uses AI to create a system for action for adults over 65 and their support networks. The main goal is to make tasks like care coordination, document management, medication adherence, and detecting changes in behavior and physical abilities easier. Chase explains, "AgeTech is more around the people in the population. So if you look at aging, it is not one point in time, but is truly a continuum and impacts so many people. It's not just the person who's aging, but also the family members and the entire circle of care around them. So, AgeTech is that kind of emerging field, which is how I try to differentiate it. Again, it's not product-centric, but it is really human-centric over a continuum of time."   "What we felt was the biggest opportunity was not only creating a solution for older adults, but creating a solution for the circle of care, the people every single day who are helping those older adults. And in parallel, we really started to lean in on this employer front with the workforce. So in the workforce environment, it's pretty interesting, 25% of FMLA is for caregiving. And right now, there's not a ton of solutions that can support them. So those workers are essentially the circle of care." #Arlow #AgeTech #AI #Healthcare #Aging #Innovation #DigitalHealth #Longevity #Caregiving #HealthTech #SeniorCare #FamilyCaregivers #CaregiverBurnout #OlderAdults #EmployeeBenefits #EmployeeAssistantPrograms Arlow.ai Listen to the podcast here

Chase Idleman, Chief Executive Officer of Arlow, is leveraging emerging AgeTech and the longevity economy to develop solutions for an aging population, their families, and caregivers. With a human-centered approach to the entire aging process, Arlow uses AI to create a system for action for adults over 65 and their support networks. The main goal is to make tasks like care coordination, document management, medication adherence, and detecting changes in behavior and physical abilities easier. Chase explains, "AgeTech is more around the people in the population. So if you look at aging, it is not one point in time, but is truly a continuum and impacts so many people. It's not just the person who's aging, but also the family members and the entire circle of care around them. So, AgeTech is that kind of emerging field, which is how I try to differentiate it. Again, it's not product-centric, but it is really human-centric over a continuum of time."   "What we felt was the biggest opportunity was not only creating a solution for older adults, but creating a solution for the circle of care, the people every single day who are helping those older adults. And in parallel, we really started to lean in on this employer front with the workforce. So in the workforce environment, it's pretty interesting, 25% of FMLA is for caregiving. And right now, there's not a ton of solutions that can support them. So those workers are essentially the circle of care." #Arlow #AgeTech #AI #Healthcare #Aging #Innovation #DigitalHealth #Longevity #Caregiving #HealthTech #SeniorCare #FamilyCaregivers #CaregiverBurnout #OlderAdults #EmployeeBenefits #EmployeeAssistantPrograms Arlow.ai Download the transcript here

Dr. Ivan Horak, Founder and CEO of Tikva Allocell, is focused on next-generation allogeneic cell therapies using modified T-cells from healthy donors to make these therapies more scalable, accessible, and affordable. Using virus-specific T-cells, this approach is showing effectiveness against solid tumors, which are difficult for traditional CAR-T therapies to treat. The primary target is an antigen found particularly in Epstein-Barr virus-associated malignancies and is showing potential for treating autoimmune diseases as well as cancer. Ivan explains, "Cell therapy has a long history. We started with many scientists, but probably the godfather of the technology, Zelig Eshhar, who's not with us anymore. He passed away last year. The idea behind that was to use patient cells and modify them and use them as a fighter against the cancer. But over time, we realized over the last two decades that it's very useful, very successful in the treatment of hematologic malignancies, but it's very expensive and labor-intensive. The question was how to enhance this technology and bring it to more patients in a friendly and affordable way." "The second generation are therapies where we are using healthy people's cells, primarily T-cells, but can be NK cells, can be gamma-delta T-cells. And these cells are being modified, and they are infused into a patient. The advantage of this technology is that patients are identified, and the provider can request the cell from different biotechnology companies, which can be available within the next few days, because from one healthy donor, you can make multiple doses for patients."  #TikvaAllocell #CellTherapy #CancerResearch #Immunotherapy #Biotechnology #Biotech #Innovation #ClinicalTrials #AllogeneicTherapy #Allogeneic #SolidTumors #NextGenTherapy #PrecisionMedicine #CellTherapy #CART #Oncology #ImmuneOncology #CellandGeneTherapy tikvaallocell.com Listen to the podcast here

Dr. Ivan Horak, Founder and CEO of Tikva Allocell, is focused on next-generation allogeneic cell therapies using modified T-cells from healthy donors to make these therapies more scalable, accessible, and affordable. Using virus-specific T-cells, this approach is showing effectiveness against solid tumors, which are difficult for traditional CAR-T therapies to treat. The primary target is an antigen found particularly in Epstein-Barr virus-associated malignancies and is showing potential for treating autoimmune diseases as well as cancer. Ivan explains, "Cell therapy has a long history. We started with many scientists, but probably the godfather of the technology, Zelig Eshhar, who's not with us anymore. He passed away last year. The idea behind that was to use patient cells and modify them and use them as a fighter against the cancer. But over time, we realized over the last two decades that it's very useful, very successful in the treatment of hematologic malignancies, but it's very expensive and labor-intensive. The question was how to enhance this technology and bring it to more patients in a friendly and affordable way." "The second generation are therapies where we are using healthy people's cells, primarily T-cells, but can be NK cells, can be gamma-delta T-cells. And these cells are being modified, and they are infused into a patient. The advantage of this technology is that patients are identified, and the provider can request the cell from different biotechnology companies, which can be available within the next few days, because from one healthy donor, you can make multiple doses for patients."  #TikvaAllocell #CellTherapy #CancerResearch #Immunotherapy #Biotechnology #Biotech #Innovation #ClinicalTrials #AllogeneicTherapy #Allogeneic #SolidTumors #NextGenTherapy #PrecisionMedicine #CellTherapy #CART #Oncology #ImmuneOncology #CellandGeneTherapy tikvaallocell.com Download the transcript here

Tyrone Lam, is Chief Business Development Officer at GATC Health, a company that has developed a predictive AI model to derisk and accelerate drug discovery and development. A significant partnership with Lloyd's of London to use this technology to underwrite insurance for clinical trials enables the insurer to base financing decisions on objective reports that predict a drug's safety and efficacy with high accuracy. There is potential for this technology to become a standard for biotech investment, reducing reliance on animal testing and enabling more efficient development of drugs for smaller patient populations.  Tyrone explains, "GATC Health is a technology company that is de-risking and accelerating the drug discovery and drug development process. So at a higher level, our mission is to take as much of the financial and scientific risk out of the drug discovery business as possible, which would enable better, safer, and more available drugs to be available for humans."   "Our overall platform is called Operon that has literally hundreds of AI models built in that basically do three things. One is that we're able to discover and validate in silico the targets in the body associated with a particular disease. And then the second piece of our platform broadly is the ability to generate novel compounds to treat those diseases. And then we created off of Operon an independent validation that would run in silico, like an AI-generated clinical trial to understand how those novel drugs would perform against those targets in human physiology."   "That third part of the platform is where we created a product called Derisq, and that is an independent, objective report that we can run on other people's drugs, biotech pharma's drug candidates, to give them a very rapid indication of how that drug's going to perform in a human clinical trial."  #GATCHealth #DrugDiscovery #AIinHealthcare #PharmaInnovation #ClinicalTrials #HealthTech #MedicalAI #Biotechnology #PrecisionMedicine #HealthcareInnovation #FutureOfMedicine #DrugDevelopment #AIplatform #DueDiligence  #DeriskingBiotech #Derisq #CapitalEfficiency #RiskIntelligence #BiotechInvesting  GATCHealth.com Listen to the podcast here

Tyrone Lam, is Chief Business Development Officer at GATC Health, a company that has developed a predictive AI model to derisk and accelerate drug discovery and development. A significant partnership with Lloyd's of London to use this technology to underwrite insurance for clinical trials enables the insurer to base financing decisions on objective reports that predict a drug's safety and efficacy with high accuracy. There is potential for this technology to become a standard for biotech investment, reducing reliance on animal testing and enabling more efficient development of drugs for smaller patient populations.  Tyrone explains, "GATC Health is a technology company that is de-risking and accelerating the drug discovery and drug development process. So at a higher level, our mission is to take as much of the financial and scientific risk out of the drug discovery business as possible, which would enable better, safer, and more available drugs to be available for humans."   "Our overall platform is called Operon that has literally hundreds of AI models built in that basically do three things. One is that we're able to discover and validate in silico the targets in the body associated with a particular disease. And then the second piece of our platform broadly is the ability to generate novel compounds to treat those diseases. And then we created off of Operon an independent validation that would run in silico, like an AI-generated clinical trial to understand how those novel drugs would perform against those targets in human physiology."   "That third part of the platform is where we created a product called Derisq, and that is an independent, objective report that we can run on other people's drugs, biotech pharma's drug candidates, to give them a very rapid indication of how that drug's going to perform in a human clinical trial."  #GATCHealth #DrugDiscovery #AIinHealthcare #PharmaInnovation #ClinicalTrials #HealthTech #MedicalAI #Biotechnology #PrecisionMedicine #HealthcareInnovation #FutureOfMedicine #DrugDevelopment #AIplatform #DueDiligence  #DeriskingBiotech #Derisq #CapitalEfficiency #RiskIntelligence #BiotechInvesting  GATCHealth.com Download the transcript here

Kristin Ashcraft, Co-Founder and CEO of OncoRx Insights, is determined to bring current information to community-based oncologists to help them identify precision therapies for their patients. The AI platform is designed to augment the oncologist's expertise by analyzing molecular diagnostics, pathology reports, and patient history to identify appropriate FDA-approved drugs and possible clinical trials. The aim is to democratize access to advanced treatment information, bringing the capabilities of academic medical centers to the community setting. Kristin explains, "Our goal is to increase the lifespan of cancer patients by enabling community oncologists to more efficiently identify precision therapies for their patients. We do this through a unique, comprehensive analysis of the molecular diagnostics, patient history, and pathology reports. The reason that we are here is that it can be summed up really well in a study that was recently published in the Journal of Clinical Oncology, in which they found that only 36% of eligible lung cancer patients receive precision medicine therapies. And so OncoRX Insights is focused on bringing greater access to precision medicine for cancer patients."   "Cancer results from genetic mutations from external or inherited causes, and it presents in over a hundred different forms. So as you pointed out, understanding the best possible treatment really is a challenge. But using the molecular diagnostic report and additional information like pathology reports, patient history, understanding those details can really help drive the most targeted treatment to have the best chance of the best outcomes for those patients." #OncoRxInsights #PrecisionMedicine #CancerCare #AIInHealthcare #Oncology #CommunityOncology #HealthTech #MedTech #CancerTreatment #DigitalHealth #PersonalizedMedicine #HealthcareInnovation #CancerResearch #HealthcareInnovation #RealWorldData OncoRxInsights.com Listen to the podcast here

Kristin Ashcraft, Co-Founder and CEO of OncoRx Insights, is determined to bring current information to community-based oncologists to help them identify precision therapies for their patients. The AI platform is designed to augment the oncologist's expertise by analyzing molecular diagnostics, pathology reports, and patient history to identify appropriate FDA-approved drugs and possible clinical trials. The aim is to democratize access to advanced treatment information, bringing the capabilities of academic medical centers to the community setting. Kristin explains, "Our goal is to increase the lifespan of cancer patients by enabling community oncologists to more efficiently identify precision therapies for their patients. We do this through a unique, comprehensive analysis of the molecular diagnostics, patient history, and pathology reports. The reason that we are here is that it can be summed up really well in a study that was recently published in the Journal of Clinical Oncology, in which they found that only 36% of eligible lung cancer patients receive precision medicine therapies. And so OncoRX Insights is focused on bringing greater access to precision medicine for cancer patients."   "Cancer results from genetic mutations from external or inherited causes, and it presents in over a hundred different forms. So as you pointed out, understanding the best possible treatment really is a challenge. But using the molecular diagnostic report and additional information like pathology reports, patient history, understanding those details can really help drive the most targeted treatment to have the best chance of the best outcomes for those patients." #OncoRxInsights #PrecisionMedicine #CancerCare #AIInHealthcare #Oncology #CommunityOncology #HealthTech #MedTech #CancerTreatment #DigitalHealth #PersonalizedMedicine #HealthcareInnovation #CancerResearch #HealthcareInnovation #RealWorldData OncoRxInsights.com Download the transcript here

Ian Crosbie, CEO of Sequana Medical, identifies the incidence of liver cirrhosis and the complication of liver ascites, which causes significant fluid buildup in the belly that severely impacts a patient's quality of life. Standard treatment requires repeated hospital visits to drain the fluid. The alfapump developed by Sequana is a fully implanted device that continuously drains ascites into the bladder for natural excretion, eliminating the need for drainage procedures. Ian explains, "Liver ascites is a complication of liver cirrhosis, a serious condition where the liver becomes badly scarred. As a result, the fluid accumulates in the belly, often five to ten liters of fluid. And as you can imagine, this causes huge swelling of the belly and major clinical problems, and obviously dramatically impacts the quality of life of these patients. Problems can include instability and falling. You can imagine with all that weight out front. The swelling of the belly causes difficulty eating, breathing, sleeping, and functioning."   "So we're in an era of AI and targeted cancer therapies, CAR-T, and things like that. But the standard of care for these patients is to let them build up five to ten liters of fluid in their bellies, then bring them into hospital, stick a big needle in them, drain them over the course of five to seven hours, send them away, and then the moment they leave hospital, they start to reaccumulate that fluid again, and the process starts all over. That is a procedure known as paracentesis. Not only is it, as you can imagine, a painful, burdensome, and traumatic procedure, but in the days leading up to the procedure, the days and weeks as the fluid starts to accumulate, all those impacts on quality of life and clinical complications occur. And so that is why we developed alfapump to stop the buildup of fluid in the belly and to stop all of those problems and to stop those regular visits to the hospital." #SequanaMedical #MedicalDevices #LiverDisease #HealthcareInnovation #PatientCare #MedTech #Alfapump #DigitalHealth #ChronicDisease #QualityOfLife #HealthTech #MedicalBreakthrough sequanamedical.com Listen to the podcast here

Ian Crosbie, CEO of Sequana Medical, identifies the incidence of liver cirrhosis and the complication of liver ascites, which causes significant fluid buildup in the belly that severely impacts a patient's quality of life. Standard treatment requires repeated hospital visits to drain the fluid. The alfapump developed by Sequana is a fully implanted device that continuously drains ascites into the bladder for natural excretion, eliminating the need for drainage procedures. Ian explains, "Liver ascites is a complication of liver cirrhosis, a serious condition where the liver becomes badly scarred. As a result, the fluid accumulates in the belly, often five to ten liters of fluid. And as you can imagine, this causes huge swelling of the belly and major clinical problems, and obviously dramatically impacts the quality of life of these patients. Problems can include instability and falling. You can imagine with all that weight out front. The swelling of the belly causes difficulty eating, breathing, sleeping, and functioning."   "So we're in an era of AI and targeted cancer therapies, CAR-T, and things like that. But the standard of care for these patients is to let them build up five to ten liters of fluid in their bellies, then bring them into hospital, stick a big needle in them, drain them over the course of five to seven hours, send them away, and then the moment they leave hospital, they start to reaccumulate that fluid again, and the process starts all over. That is a procedure known as paracentesis. Not only is it, as you can imagine, a painful, burdensome, and traumatic procedure, but in the days leading up to the procedure, the days and weeks as the fluid starts to accumulate, all those impacts on quality of life and clinical complications occur. And so that is why we developed alfapump to stop the buildup of fluid in the belly and to stop all of those problems and to stop those regular visits to the hospital." #SequanaMedical #MedicalDevices #LiverDisease #HealthcareInnovation #PatientCare #MedTech #Alfapump #DigitalHealth #ChronicDisease #QualityOfLife #HealthTech #MedicalBreakthrough sequanamedical.com Download the transcript here